A proof of concept for structure-based vaccine design targeting RSV in humans
暂无分享,去创建一个
J. Mascola | P. Kwong | B. Graham | Syed M. Moin | M. Crank | Man Chen | J. Gall | J. Ledgerwood | J. McLellan | Peifeng Chen | Azad Kumar | R. Schwartz | L. Kueltzo | S. Hickman | G. Yamshchikov | M. Nason | I. Gordon | L. Holman | P. Costner | N. Berkowitz | Ingelise J. Gordon | Pamela J M Costner | M. Gaudinski | Kaitlyn M. Morabito | Grace L. Chen | Judy A Stein | J. Cooper | Kevin Carlton | Richard M. Schwartz | Anthony T. DiPiazza | T. Ruckwardt | Emily Phung | Lauren A. Chang | J. Hill | Judy A. Stein | Pamela J. Costner
[1] M. Kanekiyo,et al. Epitope-Specific Serological Assays for RSV: Conformation Matters , 2019, Vaccines.
[2] O. Ramilo,et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. , 2018, The Lancet. Infectious diseases.
[3] A. Sivasubramanian,et al. Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation , 2018, Immunity.
[4] M. Kanekiyo,et al. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein , 2017, Nature Communications.
[5] G. Glenn,et al. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. , 2017, Vaccine.
[6] B. Graham,et al. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab , 2017, Journal of Virology.
[7] J. Stoddard,et al. Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults , 2017, Immunity & Ageing.
[8] M. Kanekiyo,et al. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state , 2017, Nature Communications.
[9] J. Crowe,et al. A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein , 2017, Nature Microbiology.
[10] R. Lamb,et al. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus , 2017, Nature Microbiology.
[11] B. Graham,et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors , 2016, Science Immunology.
[12] J. Meiler,et al. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein , 2016, Proceedings of the National Academy of Sciences.
[13] Cinque S. Soto,et al. Iterative structure-based improvement of a respiratory syncytial virus fusion glycoprotein vaccine , 2016, Nature Structural &Molecular Biology.
[14] G. Chuang,et al. Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera , 2015, Science Translational Medicine.
[15] U. Baxa,et al. Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein , 2015, PLoS pathogens.
[16] J. Wrammert,et al. Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. , 2015, American journal of respiratory and critical care medicine.
[17] Cinque S. Soto,et al. Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus , 2013, Science.
[18] U. Baxa,et al. Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody , 2013, Science.
[19] C. Palomo,et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention , 2012, Proceedings of the National Academy of Sciences.
[20] P. Kwong,et al. Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes , 2011, Journal of Virology.
[21] C. Mandl,et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers , 2011, Proceedings of the National Academy of Sciences.
[22] E. Wang,et al. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. , 2001, Vaccine.
[23] B. García-Barreno,et al. Antigenic Structure of Human Respiratory Syncytial Virus Fusion Glycoprotein , 1998, Journal of Virology.
[24] E. Walsh,et al. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. , 1998, The Journal of infectious diseases.
[25] L. Nencioni,et al. Mutants of pertussis toxin suitable for vaccine development. , 1989, Science.
[26] E. Walsh,et al. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity , 1988, Journal of clinical microbiology.
[27] E. Walsh,et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine , 1986, Journal of clinical microbiology.
[28] A. Frank,et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. , 1981, The Journal of pediatrics.
[29] R. Chanock,et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. , 1969, American journal of epidemiology.
[30] G. Meiklejohn,et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. , 1969, American journal of epidemiology.
[31] R. Chanock,et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.
[32] E. H. Lennette,et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. , 1969, American journal of epidemiology.